BackBetter Therapeutics Overview

Better Therapeutics Operating Income

Track Better Therapeutics's operating income ($-30M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

$-5341000.00
↓ 51.43% YoY

As of Sep 30, 2023

Annual Operating Income (TTM)

$-29613000.00
↓ 29.57% YoY

Trailing 12 months ending Sep 30, 2023

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin

Better Therapeutics (BTTX) FAQ

The latest operating income for BTTX is $-30M as of September 2023. That compares with $-42M in the prior-year period — up 29.6% year over year. Investors often review this figure alongside Better Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, BTTX's operating income moved from $-42M to $-30M — a 29.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Better Therapeutics's operating scale or balance-sheet position.

A operating income figure of $-30M for BTTX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BTTX's operating income ($-30M), review year-over-year change from $-42M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.